UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 7, 2009 (April 6, 2009)
Lifevantage
Corporation
(Exact name of registrant as
specified in its charter)
| Colorado | 000-30489 | 90-0224471 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 11545 W. Bernardo Court,
Suite 301, San Diego, California |
92127 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 312-8000
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.02 Unregistered Sales of Equity Securities
On April 6, 2009, Lifevantage Corporation (the “Company”) held the third and final closing of an offering to accredited investors of shares of Common Stock and warrants to purchase Common Stock (the “Offering”). The Company sold 4,460,000 shares of Common Stock of the Company at a purchase price of $0.20 per share and issued warrants exercisable for shares of Common Stock of the Company in the third closing of the Offering, for aggregate gross proceeds of $892,000 in the third closing. The Company sold an aggregate of 17,500,000 shares of Common Stock of the Company at a purchase price of $0.20 per share and issued warrants exercisable for 17,500,000 shares of Common Stock of the Company in the Offering, for aggregate gross proceeds of $3,500,000. The warrants sold in the Offering have an exercise price of $0.50 per share and may be exercised at any time following issuance during the three year exercise period.
The Company issued a warrant to purchase 1,500,000 shares of Common Stock of the Company to Aspenwood Capital as part of the consideration for services provided to the Company by Aspenwood Capital in connection with the Offering. The warrant issued to Aspenwood Capital is identical to the form of warrant issued by the Company in the Offering.
The shares and warrants were offered and sold in the Offering only to persons who meet the definition of “accredited investor” set forth in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), or to persons who are not “U.S. persons” as defined in Regulation S under the Securities Act, pursuant to exemptions from registration provided by Rule 506 of Regulation D of the Securities Act and Regulation S of the Securities Act.
Item 7.01 Regulation FD Disclosure
On April 7, 2009, the Company issued a press release entitled, “Aspenwood Capital Raises $3.5 Million for LifeVantage Corporation”. The press release is attached as Exhibit 99.1 hereto, which is furnished under Item 7.01 of this report and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Exhibits
99.1 Press release, dated April 7, 2009, entitled, “Aspenwood Capital Raises $3.5 Million for LifeVantage Corporation”.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: April 7, 2009
LIFEVANTAGE CORPORATION
By:
/s/ Bradford K. Amman
Bradford K. Amman
Chief Financial
Officer
EXHIBIT INDEX
| Exhibit No. | Description | |
|
99.1
|
Press release, dated April 7, 2009, entitled, “Aspenwood Capital Raises $3.5 Million for LifeVantage Corporation”. |
| FOR IMMEDIATE RELEASE | NEWS |
OTCBB: LFVN
LifeVantage
Patrick Courtemanche
612-746-1776
pat_court@yahoo.com
Steve J. Ossello
720-533-4888, ext 1
sossello@aspenwoodcapital.com
Aspenwood Capital (www.AspenwoodCapital.com) of Denver, Colo., a division of Colorado Financial Services Corporation (member FINRA / SIPC), specializes in providing investment banking services to small-cap public issuers and late-stage private companies.
Protandim® is a groundbreaking, clinically proven supplement that provides a substantial benefit to help with the challenge of healthy aging. This patented antioxidant therapy is more powerful than conventional foods such as red wine, oranges, blueberries or other popular antioxidant supplements. Protandim® works by increasing the body’s natural antioxidant protection at the cellular level, triggering cells to produce naturally occurring protective antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione.